In 2024 alone Freya Biosciences announced a $10 million investment, Kanvas Bio unveiled clinical data on anti-tumoral immunity impact, EnteroBiotix advances cirrhosis, the FDA allowed OpenBiome’s FMT investigation to continue, and Nexilico and Siolta Therapeutics enter collaboration for necrotizing enterocolitis. Despite funding challenges in the past few years, as microbiome awareness increases and new preclinical and clinical data emerges, the microbiome community remains committed to proving the microbiome potential to treat patients across many therapeutic areas.
What Was New for 2025
Celebrate the 10th Anniversary Awards
Join us in honoring a decade of groundbreaking achievements in microbiome research with special awards recognizing exceptional contributions and innovations in the field.
Introduce New Speakers
Gain fresh insights from newly added experts representing companies such as Pulmobiotics, Kanvas Biosciences, and Azitra.
Showcase New Companies
Discover the latest advancements from emerging companies like Alveolus Bio, Microviable Therapeutics, Unilever, Mikrobiomik, Jona, and Nestle Health Science, each presenting their innovative approaches in microbiome research.
Engage with Investors
Participate in the startup showcase, featuring an expert panel of leading investors and venture capitalists like Seventure Partners and CSB, as they evaluate and support the next generation of microbiome startups.
Attending Companies Include